Skip to main content
NCBI home page
Gut logoLink to Gut
. 1992 Apr;33(4):563–564. doi: 10.1136/gut.33.4.563

Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

E A Masson 1, J M Rhodes 1
PMCID: PMC1374079  PMID: 1582604

Abstract

Nephrotoxicity in association with 5-aminosalicylic acid therapy is well recognised. In this patient the nephrotoxicity only became apparent after severe weight loss had occurred in association with nephrogenic diabetes insipidus. The patient aged 26 with ulcerative colitis received resin coated mesalazine (Asacol) 1200 mg/day and lost 12 kg in weight over a four month period, only complaining of thirst towards the end of this period.

Full text

PDF
563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbour V. M., Williams P. F. Nephrotic syndrome associated with sulphasalazine. BMJ. 1990 Oct 6;301(6755):818–818. doi: 10.1136/bmj.301.6755.818-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cameron J. S. Allergic interstitial nephritis: clinical features and pathogenesis. Q J Med. 1988 Feb;66(250):97–115. [PubMed] [Google Scholar]
  3. Christensen L. A., Fallingborg J., Abildgaard K., Jacobsen B. A., Sanchez G., Hansen S. H., Bondesen S., Hvidberg E. F., Rasmussen S. N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. doi: 10.1111/j.1365-2036.1990.tb00499.x. [DOI] [PubMed] [Google Scholar]
  4. Dew M. J., Ebden P., Kidwai N. S., Lee G., Evans B. K., Rhodes J. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol. 1984 Apr;17(4):474–476. doi: 10.1111/j.1365-2125.1984.tb02375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dew M. J., Ryder R. E., Evans N., Evans B. K., Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983 Aug;16(2):185–187. doi: 10.1111/j.1365-2125.1983.tb04983.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hayllar J., Bjarnason I. Sulphasalazine in ulcerative colitis: in memoriam? Gut. 1991 May;32(5):462–463. doi: 10.1136/gut.32.5.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mehta R. P. Acute interstitial nephritis due to 5-aminosalicylic acid. CMAJ. 1990 Nov 15;143(10):1031–1032. [PMC free article] [PubMed] [Google Scholar]
  8. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES